# BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

> **NCT01662674** · PHASE1 · COMPLETED · sponsor: **LG Life Sciences** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** gemigliptin and metformin HCl extended release
- **DRUG:** gemigliptin/metformin HCl extended release

## Key facts

- **NCT ID:** NCT01662674
- **Lead sponsor:** LG Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2012-11
- **Final completion:** 2013-03
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2015-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01662674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01662674, "BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01662674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*